Is Becton Dickinson (BDX) Undervalued As Its Brazil Semaglutide Partnership Fuels Growth Hopes?
Becton Dickinson (BDX) is back in focus after announcing a collaboration with EMS to launch a semaglutide therapy in Brazil, using BD’s Vystra injection pen platform for chronic disease treatment.
See our latest analysis for Becton Dickinson.
Becton Dickinson’s recent collaboration news comes on the heels of a 10.92% 90 day share price return, even as the year to date share price return is down 15.04%. The 1 year total shareholder return of 22.43% points to momentum rebuilding after weaker multi year results.
If this semaglutide partnership caught your attention, it could be a good moment to see what else is shaping healthcare technology and delivery through our 41 healthcare AI stocks
Becton Dickinson now trades about 9% below the average analyst price target and around 21% below one estimate of intrinsic value, despite the semaglutide news and a recent share rebound. Is the market’s caution still warranted?
Most Popular Narrative: 8.6% Undervalued
Becton Dickinson’s most followed narrative pegs fair value at $181.23, a touch above the latest $165.62 close, which keeps the valuation debate very much alive.
The pending separation of the Biosciences and Diagnostic Solutions business will transform BD into a pure-play medical technology leader with a consumables-heavy portfolio (>90% of revenue). This is expected to enable higher cash flow predictability and margin improvement, while anticipated aggressive share buybacks directly support EPS growth.
Want to see how this Becton Dickinson breakup story ties together margins, cash flows, and future valuation multiples? The key assumptions behind that target may surprise you.
Result: Fair Value of $181.23 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Becton Dickinson still faces meaningful risks around trade tariffs that could pressure margins, as well as the complex Biosciences and Diagnostics separation that could introduce unforeseen costs.
Find out about the key risks to this Becton Dickinson narrative.
Next Steps
If the mixed tone on Becton Dickinson leaves you unsure, this is a good moment to review the data yourself and form a view quickly. To see both sides clearly, including the key risks and rewards that other investors are watching, check out the 5 key rewards and 2 important warning signs
Looking for more Becton Dickinson investment ideas?
Before you move on from Becton Dickinson, take a few minutes to scan fresh opportunities with the Simply Wall Street Screener so you are not leaving potential ideas on the table.
- Target potential mispricings by reviewing companies that screen as 55 high quality undervalued stocks and see which ones deserve a closer look.
- Focus on resilience first and hunt for stocks highlighted in the 81 resilient stocks with low risk scores that may suit a steadier approach.
- Get ahead of the crowd by checking the screener containing 19 high quality undiscovered gems and see which less followed stocks match your criteria.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com